INmune Bio Announces Upcoming Webinar on New RDEB Treatment Data

Clinical investigators to share real-world experience and data on CORDStrom™ for recessive dystrophic epidermolysis bullosa

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

INmune Bio Inc. will host a webinar on February 26, 2026 to present new clinical data on its CORDStrom™ treatment for recessive dystrophic epidermolysis bullosa (RDEB). The webinar will feature insights from the principal investigators of the MissionEB Phase III clinical trial, focusing on CORDStrom™’s systemic disease-modifying capabilities beyond just topical wound care.

Why it matters

RDEB is a rare and debilitating genetic skin disorder that causes severe blistering and scarring. Current standard-of-care options are limited to topical treatments, while CORDStrom™ is being developed as a systemic, disease-modifying therapy. The upcoming webinar aims to showcase new data demonstrating CORDStrom™’s potential to address the broader, systemic impacts of RDEB.

The details

The webinar will highlight data from the MissionEB Phase III clinical trial, including improvements in EBDASI skin scores, evidence of weight gain in pediatric patients, reductions in pain and itch, and enhanced quality of life measures. The featured speakers will be Dr. Anna Martinez, the principal investigator of the MissionEB study, and Prof. Mark Lowdell, the Chief Scientific Officer and Co-Founder of INmune Bio.

  • The webinar will be held on February 26, 2026 at 1:00 p.m. ET.

The players

INmune Bio Inc.

A late-stage biotechnology company focused on inflammation and immunology, developing treatments that target the innate immune system.

Dr. Anna Martinez

The principal investigator of the MissionEB clinical trial and the United Kingdom's leading specialist in pediatric RDEB, internationally recognized for her expertise in rare and complex skin disorders.

Prof. Mark Lowdell

The Chief Scientific Officer and Co-Founder of INmune Bio, as well as Professor of Cell and Tissue Therapy at University College London, where he has led a translational immunotherapy group since 1994.

Got photos? Submit your photos here. ›

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This webinar highlights the potential of CORDStrom™ to address the broader, systemic impacts of RDEB, going beyond just topical wound care. The new data could signal a significant advancement in the treatment of this rare and debilitating genetic skin disorder.